Correction: Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party

Bone Marrow Transplantation

by Jesús Duque-Afonso, Jürgen Finke, Allain-Thibeault Ferhat, Jacques-Emmanuel Galimard, Francesca Kinsella, Deborah Richardson, Friedrich Stölzel, Eleni Tholouli, Caroline Besley, Matthias Eder, Emma Nicholson, Robert Zeiser, Adrian Bloor, Charles Crawley, Katherine Clesham, Jennifer Byrne, Patrick Medd, Elisa Sala, Caroline Pabst, Jan Vydra, Eva Maria Wagner-Drouet, Alain Gadisseur, Alexandros Spyridonidis, Eolia Brissot, Arnon Nagler, Mohamad Mohty, Fabio Ciceri
October 23, 2026

Jama Network Open

Blood Cancer Journal

Journal Of Neuro-Oncology

Correction: Registry comparison of ATG and alemtuzumab for in vivo T-cell depletion in GVHD prophylaxis among unrelated-donor allo-HCT recipients with AML and intermediate-intensity conditioning, on behalf of the EBMT Acute Leukemia Working Party